Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H18ClN3O3S.ClH |
| Molecular Weight | 392.301 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OCCN1CCN(CC1)C(=O)CN2C(=O)SC3=C2C=C(Cl)C=C3
InChI
InChIKey=UKNGDQSYPNBJAO-UHFFFAOYSA-N
InChI=1S/C15H18ClN3O3S.ClH/c16-11-1-2-13-12(9-11)19(15(22)23-13)10-14(21)18-5-3-17(4-6-18)7-8-20;/h1-2,9,20H,3-8,10H2;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C15H18ClN3O3S |
| Molecular Weight | 355.84 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Tiaramide is an anti-inflammatory and analgesic drug, which was developed by Fujisawa Pharmaceutical (now Astellas pharma) and used in Japan under the name Solantol for the treatment of different pain and inflammatory disorders. Later on, Astellas recalled the product by reasons other than safety. The mechanism of tiaramide action is unknown.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | SOLANTAL Approved UsePain management after surgery, tooth extraction and trauma, pain relief in arthritis, low back pain, cervical shoulder arm syndrome, pelvic inflammation, birth canal injuries, breast engorgement, herpes zoster, polymorphic exudative erythema, cystitis, epididymitis, uveitis, pericoronitis, acute upper respiratory tract inflammation. Launch Date1974 |
|||
| Palliative | SOLANTOL Approved UsePain management after surgery, tooth extraction and trauma, pain relief in arthritis, low back pain, cervical shoulder arm syndrome, pelvic inflammation, birth canal injuries, breast engorgement, herpes zoster, polymorphic exudative erythema, cystitis, epididymitis, uveitis, pericoronitis, acute upper respiratory tract inflammation. Launch Date1974 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.79 μg/mL |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TIARAMIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6125356/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TIARAMIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.36 μg × h/mL |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TIARAMIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.59 h |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TIARAMIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.34 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6125356/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TIARAMIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
51% |
TIARAMIDE plasma | Homo sapiens |
Doses
| Dose | Population | Adverse events |
|---|---|---|
500 mg 2 times / day multiple, oral Highest studied dose Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Disc. AE: Loss of consciousness... Other AEs: Seizures... AEs leading to discontinuation/dose reduction: Loss of consciousness Other AEs:Seizures Sources: |
200 mg 4 times / day multiple, oral Recommended Dose: 200 mg, 4 times / day Route: oral Route: multiple Dose: 200 mg, 4 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Disc. AE: Convulsion... Other AEs: Loss of consciousness... AEs leading to discontinuation/dose reduction: Convulsion Other AEs:Loss of consciousness Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Seizures | 500 mg 2 times / day multiple, oral Highest studied dose Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
|
| Loss of consciousness | Disc. AE | 500 mg 2 times / day multiple, oral Highest studied dose Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
| Loss of consciousness | 200 mg 4 times / day multiple, oral Recommended Dose: 200 mg, 4 times / day Route: oral Route: multiple Dose: 200 mg, 4 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
|
| Convulsion | Disc. AE | 200 mg 4 times / day multiple, oral Recommended Dose: 200 mg, 4 times / day Route: oral Route: multiple Dose: 200 mg, 4 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. | 2008-10-31 |
|
| Synthesis and anti-inflammatory activity of certain piperazinylthienylpyridazine derivatives. | 2007-07 |
|
| Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide. | 2007-03 |
|
| Strategy for structure elucidation of drug metabolites derived from protonated molecules and (MS)n fragmentation of zotepine, tiaramide and their metabolites. | 2002 |
Sample Use Guides
The recommended dose is 1 tablet (100 mg) once daily. In patients with acute upper respiratory tract inflammation the dose may be increased up to 3 tablets.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/451335
Tiaramide in 10(-4) and 10(-5)M inhibited effectively the platelet aggregation caused by ADP.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:46:40 GMT 2025
by
admin
on
Mon Mar 31 18:46:40 GMT 2025
|
| Record UNII |
ITY1616X9T
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C319
Created by
admin on Mon Mar 31 18:46:40 GMT 2025 , Edited by admin on Mon Mar 31 18:46:40 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
252-802-7
Created by
admin on Mon Mar 31 18:46:40 GMT 2025 , Edited by admin on Mon Mar 31 18:46:40 GMT 2025
|
PRIMARY | |||
|
SUB04855MIG
Created by
admin on Mon Mar 31 18:46:40 GMT 2025 , Edited by admin on Mon Mar 31 18:46:40 GMT 2025
|
PRIMARY | |||
|
C152604
Created by
admin on Mon Mar 31 18:46:40 GMT 2025 , Edited by admin on Mon Mar 31 18:46:40 GMT 2025
|
PRIMARY | |||
|
ITY1616X9T
Created by
admin on Mon Mar 31 18:46:40 GMT 2025 , Edited by admin on Mon Mar 31 18:46:40 GMT 2025
|
PRIMARY | |||
|
289337
Created by
admin on Mon Mar 31 18:46:40 GMT 2025 , Edited by admin on Mon Mar 31 18:46:40 GMT 2025
|
PRIMARY | |||
|
443949
Created by
admin on Mon Mar 31 18:46:40 GMT 2025 , Edited by admin on Mon Mar 31 18:46:40 GMT 2025
|
PRIMARY | |||
|
m10849
Created by
admin on Mon Mar 31 18:46:40 GMT 2025 , Edited by admin on Mon Mar 31 18:46:40 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000084916
Created by
admin on Mon Mar 31 18:46:40 GMT 2025 , Edited by admin on Mon Mar 31 18:46:40 GMT 2025
|
PRIMARY | |||
|
DTXSID6048757
Created by
admin on Mon Mar 31 18:46:40 GMT 2025 , Edited by admin on Mon Mar 31 18:46:40 GMT 2025
|
PRIMARY | |||
|
CHEMBL274239
Created by
admin on Mon Mar 31 18:46:40 GMT 2025 , Edited by admin on Mon Mar 31 18:46:40 GMT 2025
|
PRIMARY | |||
|
35941-71-0
Created by
admin on Mon Mar 31 18:46:40 GMT 2025 , Edited by admin on Mon Mar 31 18:46:40 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |